Estimated prevalence of advanced fibrosis in 264 fatty liver subjects based on clinical prediction formulae
| Formulae | Cut-off | n | 95% CI |
| AST/ALT ratio | 1.0 | 32 (12.1%) | 8.2% to 16.1% |
| APRI* | 0.5 | 12 (4.5%) | 2.0% to 7.1% |
| 1.5 | 0 | 0 to 0 | |
| FIB-4* | 1.30 | 26 (9.8%) | 6.3% to 13.4% |
| 2.67 | 1 (0.4%) | 0 to 1.1% | |
| NAFLD fibrosis score* | −1.455 | 43 (16.3%) | 0 to 20.7% |
| 0.676 | 0 | 0 to 0 | |
| BARD score | 2 | 16 (6.1%) | 3.2% to 8.9% |
↵* The lower cut-off values had high sensitivity in excluding advanced fibrosis, while the higher cut-off values had high specificity in ruling in advanced fibrosis.
ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; NAFLD, non-alcoholic fatty liver disease.